Pharmacoeconomic analysis of ciclopirox nail lacquer solution 8% and the new oral antifungal agents used to treat dermatophyte toe onychomycosis in the United States

Journal of the American Academy of Dermatology

Volumn 43, Issue 4 SUPPL., 2000, Pages

  Gupta, Aditya K ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CICLOPIROX; FLUCONAZOLE; GRISEOFULVIN; ITRACONAZOLE; TERBINAFINE;

ANTIFUNGAL ACTIVITY; ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; HUMAN; ONYCHOMYCOSIS; PRIORITY JOURNAL;

EID: 0033784040     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1067/mjd.2000.109069     Document Type: Article

References (146)

1. Antifungal agents: An overview. Part I
2. Antifungal agents: An overview. Part II
3. A multinational pharmacoeconomic analysis of oral therapies for onychomycosis
4. Economic evaluation of antifungal agents in the treatment of toenail onychomycosis in Germany
5. Pharmacoeconomic analysis of oral antifungal therapies used to treat dermatophyte onychomycosis of the toe-nails: A US analysis
6. The new oral agents for onychomycosis of the toenails
7. An update, with a risk-benefit evaluation of the newer oral antifungal agents to treat onychomycosis
8. Pharmacokinetic properties
9. Ketoconazole-induced fulminant hepatitis necessitating liver transplantation
10. Ketoconazole
11. Current management of onychomycosis: An overview
12. Itraconazole pulse therapy is effective in the treatment of onychomycosis: A pharmacokinetic/pharmacodynamic and clinical evaluation
13. Fluconazole for the treatment of onychomycosis: An update
14. Onychomycosis treated with itraconazole or griseofulvin alone with and without a topical antimycotic or keratolytic agent
15. Comparative multicenter double-blind study of terbinafine (250 mg per day) versus griseofulvin (1 g per day) in the treatment of dermatophyte onychomycosis
16. Double-blind, parallel-group comparison of terbinafine and griseofulvin in the treatment of toenail onychomycosis
17. Treatment of toenail onychomycosis: A randomized, double-blind study with terbinafine and griseofulvin
18. Itraconazole in onychomycosis: Open and double-blind studies
19. Open randomized comparison of itraconazole versus terbinafine in onychomycosis
20. Randomized double blind comparison of terbinafine and itraconazole for treatment of toenail tinea infection
21. A 12-week treatment for dermatophyte toe onychomycosis: Terbinafine 250 mg/day vs itraconazole 200 mg/day - A double-blind comparative trial
22. Randomized double-blind comparison of short term itraconazole and terbinafine therapy for toenail onychomycosis
23. Double-blind, randomized comparison of itraconazole capsules vs placebo in the treatment of toenail onychomycosis
24. The use of itraconazole in onychomycosis
25. Itraconazole in the treatment of onychomycosis: A double-blind comparison with miconazole
26. A double-blind, randomized study comparing itraconazole pulse therapy with continuous dosing for the treatment of toenail onychomycosis
27. Itraconazole versus terbinafine (Lamisil): Which is better for the treatment of onychomycosis?
28. Double-blind, randomized comparison of itraconazole capsules and placebo in the treatment of onychomycosis of the toenail
29. A double blind randomized comparison of itraconazole capsules and placebo in the treatment of onychomycosis of the toenail
30. Itraconazole in onychomycosis: Intermittent dose schedule
31. Double-blind randomized study of continuous terbinafine compared with intermittent itraconazole in the treatment of toenail onychomycosis
32. An intermittent 1-week dosing regimen for the treatment of toenail onychomycosis in dermatological patients
33. The safety and efficacy of intermittent therapy with itraconazole for finger and toenail onychomycosis: A multicenter trial
34. Itraconazole pulse therapy vs terbinafine continuous dosing for toenail onychomycosis
35. Treatment of onychomycosis due to mycelial fungi
36. Treatment of dermatophyte nail infections: An open randomized study comparing intermittent terbinafine therapy with continuous terbinafine treatment and intermittent itraconazole therapy
37. Therapeutic efficacy and safety of 1-week intermittent therapy with itraconazole for onychomycosis in a Chinese patient population
38. Intermittent therapy with terbinafine for dermatophyte toe onychomycosis: A new approach
39. Terbinafine (Lamisil) 250 mg/day and 500 mg/day are equally effective in a 16 week oral treatment of toenail onychomycosis: A double-blind multicentre trial
40. Short-term treatment of dermatophyte onychomycosis with terbinafine
41. A study to compare the efficacy of Lamisil (terbinafine) and Diflucan (fluconazole) in patients with onychomycosis [abstract]. Poster 132
42. Oral terbinafine in toenail dermatophytosis
43. Evaluation of 6 weeks treatment of terbinafine in tinea unguium in a double-blind trial comparing 6 and 12 weeks therapy
44. A randomized treatment duration-finding study of terbinafine in onychomycosis
45. Terbinafine in onychomycosis of the toenail: A novel treatment protocol
46. An open-label, non-comparative, multicenter evaluation of fluconazole with or without urea nail pedicure for treatment of onychomycosis
47. Fluconazole in the treatment of severe onychomycosis
48. Once-weekly fluconazole (150 mg, 300 mg, or 450 mg) in the treatment of distal subungual onychomycosis of the toe-nail
49. Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis
50. Experiences in one hundred thirty-seven patients with oral griseofulvin
51. Comparative effects of griseofulvin on onychomycosis and on psoriasis
52. Griseofulvin and Trichophyton rubrum infections
53. Mycological and clinical evaluation of griseofulvin for chronic onychomycosis
54. Treatment of tinea unguium with medium and high doses of ultramicrosize griseofulvin compared with that with itraconazole
55. Chronic ringworm infection of the skin and nails treated with griseofulvin
56. A comparative double-blind study of ketoconazole and griseofulvin in dermatophytosis
57. Efficacy and safety of itraconazole in the long-term treatment of onychomycosis
58. Chronic ringworm of the nails
59. Use of griseofulvin in office practice
60. Onychomycosis treated with ultrafine griseofulvin
61. Dosage requirements of griseofulvin in onychomycosis due to Trichophyton rubrum
62. Griseofulvin for the systemic treatment of dermatomycoses
63. Short-term treatment of onychomycosis with griseofulvin
64. New schemes in the treatment of dermatophytoses with griseofulvin
65. Short-duration treatment of fingernail dermatophytosis: A randomized, double-blind study with terbinafine and griseofulvin
66. The treatment of onychomycosis with griseofulvin
67. Onychomycosis caused by Microsporum canis: Treatment with itraconazole
68. Itraconazole therapy for recalcitrant dermatophyte infections
69. Treatment of onychomycosis with itraconazole
70. An evaluation of itraconazole in the management of onychomycosis
71. Candidiasis endocrinopathy syndrome
72. Efficacy and tolerability of itraconazole in patients with fingernail onychomycosis: A 6-week pilot study
73. Itraconazole therapy is effective for pedal onychomycosis caused by some non-dermatophyte molds and in mixed infection with dermatophytes and molds: A multicenter study with 35 patients
74. Candida onychomycosis: An evaluation of the role of Candida species in nail disease
75. Itraconazole therapy for onychomycosis: Case reports
76. Itraconazole in the treatment of two young brothers with chronic mucocutaneous candidiasis
77. Posttreatment itraconazole levels in the nail
78. Pulse therapy with one-week itraconazole monthly for three or four months in the treatment of onychomycosis
79. Small-dose itraconazole pulse therapy in the treatment of onychomycosis
80. Efficacy and safety of itraconazole pulse therapy: Brazilian multicentric study on toenail onychomycosis caused by dermatophytes
81. Yellow nail syndrome and onychomycosis
82. Trichophyton rubrum onychomycosis in a 17-year-old girl
83. A multicenter, placebo-controlled, double-blind study of intermittent therapy with itraconazole for the treatment of onychomycosis of the fingernail
84. A comparison among four regimens of itraconazole treatment in onychomycosis
85. Onychomycosis treated with a short course of oral terbinafine
86. Short therapy for tinea unguium with terbinafine: Four different courses of treatment
87. Terbinafine and onychomycosis
88. Single dose treatment of fungal nail disease
89. Management of onychomycosis with oral terbinafine
90. Treatment of onychomycosis with terbinafine
91. Treatment of dermatophyte infection of the finger- and toe-nails with terbinafine (SF 86-327, Lamisil), an orally active fungicidal agent
92. Short-duration therapy with terbinafine for dermatophyte onychomycosis: A multicentre trial
93. Clinical results with terbinafine in onychomycosis
94. The successful treatment of finger Trichophyton rubrum onychomycosis with oral terbinafine
95. Terbinafine in onychomycosis: A mini study
96. Terbinafine and onychomycosis
97. Very short duration therapy with oral terbinafine for fingernail onychomycosis
98. Terbinafine in onychomycosis with involvement by non-dermatophytic fungi
99. Treatment of Candida nail infections with terbinafine
100. Terbinafine in chronic paronychia and Candida onychomycosis
101. Onychomycosis due to Scopuloriopsis brevicaulis: Clinical features and response to systemic antifungals
102. Study of the efficacy and tolerability of oral terbinafine in the treatment of onychomycosis in renal transplant patients
103. Treatment of onychomycosis with terbinafine in patients with Down's syndrome
104. Long-term post-treatment follow-up of onychomycosis treated with terbinafine: A multicentre trial
105. Very short duration therapy with oral terbinafine for fingernail onychomycosis
106. Use of terbinafine in HIV-positive subjects: Pilot studies in onychomycosis and oral candidiasis
107. Toenail onychomycosis in patients with acquired immune deficiency syndrome: Treatment with terbinafine
108. Terbinafine vs placebo for onychomycosis in black patients
109. Fluconazole in the treatment of onychomycosis caused by dermatophytes
110. Once-weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the fingernail
111. Once-weekly fluconazole (450 mg) for 4, 6, or 9 months of treatment for distal subungual onychomycosis of the toenail
112. Pharmacokinetics of three doses of once-weekly fluconazole (1250, 300, and 450 mg) in distal subungual onychomycosis of the toenail
113. Pharmacokinetics of three once-weekly dosages of fluconazole (150, 300, or 450 mg) in distal subungual onychomycosis of the fingernail
114. Intermittent fluconazole dosing in patients with onychomycosis: Results of a pilot study
115. Successful treatment of onychomycosis with fluconazole in two patients with hyperimmunoglobulin E syndrome
116. An evaluation of the safety and efficacy of fluconazole in the treatment of onychomycosis
117. Recalcitrant onychomycosis of the toenails successfully treated with fluconazole
118. Onychomycosis: Successful treatment with once-weekly fluconazole
119. The safety and efficacy of oral fluconazole in the treatment of onychomycosis
120. Meta-analysis in clinical trials
121. Meta-analysis for combining Bayesian probabilities
122. Special features of the clinical use of oral terbinafine in the treatment of fungal diseases
123. Itraconazole pulse therapy for onychomycosis and dermatomycoses: An overview
124. Once-weekly fluconazole in the treatment of onychomycosis
125. Pharmacoeconomic analysis of the new oral antifungal agents used to treat toenail onychomycosis in the USA
126. Dermatopharmacology of ciclopirox nail lacquer, topical solution 8% in the treatment of onychomycosis
127. Hydroxy-pyridones outstanding biological properties
128. The role of ciclopirox nail lacquer solution 8% in the 21st century
129. Oral antifungal drug interactions
130. Drug interactions with itraconazole, fluconazole, and terbinafine, and their management
131. Adverse drug reactions in the elderly and their prevention
132. Important drug-drug interactions in the elderly
133. HIV protease inhibitors: Pharmacologic and metabolic distinctions
134. Pharmacoeconomic analysis of oral therapies for onychomycosis: A US model
135. Modeling the cost-effectiveness of oral therapy for nail fungus
136. A cost/efficacy analysis of oral antifungals indicated for the treatment of onychomycosis: Griseofulvin, itraconazole, and terbinafine
137. Cost-effectiveness of two new treatments for onychomycosis: An analysis of two comparative clinical trials